PhaseBio Pharmaceuticals Long-term assets (Other)

Long-term assets (Other) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-term assets (Other) growth rates and interactive chart. All other non-current assets that do not fit the categories above.


Highlights and Quick Summary

  • Long-term assets (Other) for the quarter ending September 29, 2021 was $57 Thousand (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Long-term assets (Other) decreased by 0.0%
  • Annual Long-term assets (Other) for 2020 was $57 Thousand (a 78.13% increase from previous year)
  • Annual Long-term assets (Other) for 2019 was $32 Thousand (a -25.58% decrease from previous year)
  • Annual Long-term assets (Other) for 2018 was $43 Thousand (a 38.71% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-term assets (Other) of PhaseBio Pharmaceuticals

Most recent Long-term assets (Other)of PHAS including historical data for past 10 years.

Interactive Chart of Long-term assets (Other) of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Long-term assets (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.06 $0.06 $0.06
2020 $0.06 $0.06 $0.06 $0.03 $0.06
2019 $0.03 $0.03 $0.03 $0.03 $0.03
2018 $0.04 $0.05 $0.04
2017 $0.03
2016 $0.03

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.